Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03392337 · ClinicalTrials.gov registry record · NA

An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

A NA study of Psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT03392337 is a NA study of Psoriasis that is actively recruiting participants, run by Psoriasis Treatment Center of Central New Jersey. The registered enrollment target is 30 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03392337, a NA study of Psoriasis, is actively recruiting participants, sponsored by Psoriasis Treatment Center of Central New Jersey.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.

Conditions Studied

Interventions

  • DEVICE Narrowband UVB phototherapy

Study Locations (1)

New Jersey

  • Elise Nelson - East Windsor

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2017-11-07
Est. Completion 2020-01-01
Phase NA

What the Registry Record Tells You About NCT03392337

The ClinicalTrials.gov registry entry for NCT03392337 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower). The listed sponsor is Psoriasis Treatment Center of Central New Jersey, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Narrowband UVB phototherapy is the first listed.

NCT03392337 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT03392337 about?

NCT03392337 is a clinical study titled "An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients". A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.

What is the current status of trial NCT03392337?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2017-11-07. Estimated completion is 2020-01-01.

What conditions does trial NCT03392337 study?

This clinical trial studies the following conditions: Psoriasis.

What interventions are being tested in trial NCT03392337?

The interventions under investigation include: Narrowband UVB phototherapy (DEVICE).

Who is sponsoring clinical trial NCT03392337?

This trial is sponsored by Psoriasis Treatment Center of Central New Jersey, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03392337 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.